Liquid Biopsy Market Research Report by Product, Sample, Type, Technology, Indication, End-User, Application, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, High Inflation

Description

List of Tables

The Global Liquid Biopsy Market size was estimated at USD 1,417.69 million in 2022 and expected to reach USD 1,704.64 million in 2023, projecting growth at a CAGR of 20.37% to reach USD 6,250.89 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Liquid Biopsy Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people's lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Liquid Biopsy Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Liquid Biopsy Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Liquid Biopsy Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the Global Liquid Biopsy Market in order to forecast the revenues and analyze the trends in each of the following sub-markets.

Based on Product, the market is studied across Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, Exosome, and Extracellular Vesicles.

Based on Sample, the market is studied across Blood Based and Urine Based.

Based on Type, the market is studied across Assay Kits, Instruments, and Services.

Based on Technology, the market is studied across Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays.

Based on Indication, the market is studied across Cancer Indication and Non-Cancer Indication. The Cancer Indication is further studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer.

Based on End-User, the market is studied across Academic & Research Centers, Clinical Diagnostic Laboratories, Hospitals, and Physician's Office Laboratories.

Based on Application, the market is studied across Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring.

Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Liquid Biopsy Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Liquid Biopsy Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Liquid Biopsy Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Liquid Biopsy Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor's strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Liquid Biopsy Market, including Bio-Rad Laboratories, Inc., Biocept, Inc., Exact Sciences Corporation, Foundation Medicine, Inc., Freenome Holdings, Inc., Guardant Health, Inc., Illumina, Inc., LungLife AI, Inc., Mdxhealth SA, Mesa Labs, Inc., Myriad Genetics, Inc., Natera, Inc., Neogenomics, Inc., PerkinElmer, Inc., Strand Life Sciences Pvt. Ltd., and Thermo Fisher Scientific Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Liquid Biopsy Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Liquid Biopsy Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Liquid Biopsy Market?

4. What is the competitive strategic window for opportunities in the Global Liquid Biopsy Market?

5. What are the technology trends and regulatory frameworks in the Global Liquid Biopsy Market?

6. What is the market share of the leading vendors in the Global Liquid Biopsy Market?

7. What modes and strategic moves are considered suitable for entering the Global Liquid Biopsy Market?

Product Code: MRR-43470FC608C9

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising Incidence and Prevalence of Cancer
  - 5.1.1.2. Increasing Preference for Noninvasive Diagnostic Procedures
  - 5.1.1.3. Availability of Funding to Expand Cancer Research in the Field of Liquid Biopsy
- 5.1.2. Restraints
  - 5.1.2.1. Low Abundance and Fragile Nature of the Circulating Tumor Cells (CTCs)
- 5.1.3. Opportunities
  - 5.1.3.1. Significant use of Microarrays and Next-Generation Sequencing (NGS)
  - 5.1.3.2. Ongoing Development of Advanced Liquid Biopsy Assays
- 5.1.4. Challenges
  - 5.1.4.1. Unclear Regulatory and Reimbursement Scenario
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Threat of Substitutes
- 5.5.4. Threat of Substitutes
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Liquid Biopsy Market, by Product

6.1. Introduction
6.2. Cell-free DNA
6.3. Circulating Tumor Cells
6.4. Circulating Tumor DNA
6.5. Exosome
6.6. Extracellular Vesicles

7. Liquid Biopsy Market, by Sample

7.1. Introduction
7.2. Blood Based
7.3. Urine Based

8. Liquid Biopsy Market, by Type

8.1. Introduction
8.2. Assay Kits
8.3. Instruments
8.4. Services

9. Liquid Biopsy Market, by Technology

9.1. Introduction
9.2. Multi-gene Parallel Analysis using NGS
9.3. Single-gene Analysis using PCR Microarrays

10. Liquid Biopsy Market, by Indication

10.1. Introduction
10.2. Cancer Indication
- 10.3.1. Breast Cancer
- 10.3.2. Colorectal Cancer
- 10.3.3. Lung Cancer
- 10.3.4. Melanoma
- 10.3.5. Prostate Cancer
10.3. Non-Cancer Indication

11. Liquid Biopsy Market, by End-User

11.1. Introduction
11.2. Academic & Research Centers
11.3. Clinical Diagnostic Laboratories
11.4. Hospitals
11.5. Physician's Office Laboratories

12. Liquid Biopsy Market, by Application

12.1. Introduction
12.2. Early Cancer Screening
12.3. Recurrence Monitoring
12.4. Therapy Selection
12.5. Treatment Monitoring

13. Americas Liquid Biopsy Market

13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States

14. Asia-Pacific Liquid Biopsy Market

14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam

15. Europe, Middle East & Africa Liquid Biopsy Market

15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom

16. Competitive Landscape

16.1. FPNV Positioning Matrix
- 16.1.1. Quadrants
- 16.1.2. Business Strategy
- 16.1.3. Product Satisfaction
16.2. Market Ranking Analysis, By Key Player
16.3. Market Share Analysis, By Key Player
16.4. Product Portfolio Analysis, By Key Player
16.5. Competitive Scenario
- 16.5.1. Merger & Acquisition
- 16.5.2. Agreement, Collaboration, & Partnership
- 16.5.3. New Product Launch & Enhancement
- 16.5.4. Investment & Funding
- 16.5.5. Award, Recognition, & Expansion

17. Company Usability Profiles

17.1. Bio-Rad Laboratories, Inc.
17.2. Biocept, Inc.
17.3. Exact Sciences Corporation
17.4. Foundation Medicine, Inc.
17.5. Freenome Holdings, Inc.
17.6. Guardant Health, Inc.
17.7. Illumina, Inc.
17.8. LungLife AI, Inc.
17.9. Mdxhealth SA
17.10. Mesa Labs, Inc.
17.11. Myriad Genetics, Inc.
17.12. Natera, Inc.
17.13. Neogenomics, Inc.
17.14. PerkinElmer, Inc.
17.15. Strand Life Sciences Pvt. Ltd.
17.16. Thermo Fisher Scientific Inc.

18. Appendix

18.1. Discussion Guide
18.2. License & Pricing